Tag Archives: drugs

Quick Announcement

Finally (!) I am able to share the news that I’ve been invited to serve on a panel at the upcoming FDA Drug Development for ME/CFS Workshop. I’ve wanted to announce this for awhile, but panelists were asked not to … Continue reading

Posted in Advocacy | Tagged , , , , , , , , , , | 7 Comments

Tell It To The FDA

The much anticipated FDA meeting on drug development for ME/CFS on April 25-26th is fast approaching, and your participation is needed! There is a great deal of time set aside for patient input, but the process will work very differently … Continue reading

Posted in Advocacy | Tagged , , , , , , , , , | 6 Comments

Ampligen is Not AZT

In recent weeks, some ME/CFS advocates have been calling for NIH to conduct a clinical trial of Ampligen based on the reasoning that NIH conducted trials of AZT during the early years of the AIDS crisis. Unfortunately, this analogy does … Continue reading

Posted in Advocacy, Commentary | Tagged , , , , , , , , , , | 10 Comments

Speeding Things Up

In my previous post, I explained the definitions FDA used to determine that CFS is a serious or life-threatening condition. But the true significance of FDA’s decision is that it makes CFS treatments eligible for programs that speed up the … Continue reading

Posted in Advocacy | Tagged , , , , , , , , , , | 1 Comment

Serious Or Life-Threatening

During the stakeholder teleconference with FDA on September 13, 2012, Dr. Sandra Kweder said that FDA considers ME/CFS to be a serious or life-threatening condition. In the world of FDA regulations, this is a very important designation. Here’s the full … Continue reading

Posted in Advocacy | Tagged , , , , , , , , , | 4 Comments

FDA Webinar on Advocacy

Yesterday, the FDA hosted a webinar for the ME/CFS community on “Working Together for Change.” Their stated goal was to show what has been successful for patient groups in the past in working with FDA and other entities. The slides … Continue reading

Posted in Advocacy | Tagged , , , , , , , , | 12 Comments